Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4)

Background: In a prior Phase III, randomized-withdrawal study, osilodrostat, a potent oral 11β-hydroxylase inhibitor, provided rapid and sustained normalization of mean urinary free cortisol (mUFC) in most patients (pts) with CD. Now, we report efficacy and safety results from another Phase III stud...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Endocr Soc
Prif Awduron: Gadelha, Mônica, Bex, Marie, Feelders, Richard A, Heaney, Anthony P, Auchus, Richard J, Gilis-Januszewska, Aleksandra, Witek, Przemyslaw, Belaya, Zhanna, Liao, Zhihong, Ku, Chih Hao Chen, Carvalho, Davide, Roughton, Michael, Wojna, Judi, Hofstetter, Georg, Pedroncelli, Alberto M, Snyder, Peter J
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2021
Pynciau:
Neuroendocrinology and Pituitary
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090763/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1055
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg